What happened
The FDA confirmed it is reviewing marketing claims and ingredient sourcing for several leading topical exosome products. The agency reiterated that exosome products marketed for clinical effects in the US require investigational new drug pathways for injectables. The cosmetic topical use category is less clear, but the agency signaled that "structure/function" claims hinting at clinical regeneration may cross the line.
Why it matters
- Multiple high-priced topical exosome products imply more than cosmetic effect in their copy. Expect a wave of relabeling.
- Some clinics use injectable exosomes adjunctively after microneedling, RF microneedling, or PRP. That practice may face stricter enforcement.
- Consumer-facing brands sourcing exosomes from human-derived cell cultures could see import or labeling complications.
- Plant-derived exosome lines may sit further from the enforcement crosshairs, but their evidence is even thinner.
What to watch next
- Formal guidance from the FDA on cosmetic vs drug claims for vesicle-based topicals.
- Reaction from professional societies (AAD, ASDS) on in-office injectable practice.
- Brand recalls or claim changes on existing topical exosome lines.
- EU and UK regulator responses; cosmetic and biotech rules differ significantly.